NGM Biopharmaceuticals Gets $50M For Diabetes, Obesity Treatments
South San Francisco-based NGM Biopharmaceuticals said last week that it has raised $50M in a Series C funding round, to go towards its development of therapeutics for the treatment of diabetes, obesity and other cardio‐metabolic diseases. The funding included the Topspin Fund, as well as existing investors The Column Group, Prospect Venture
Partners, Rho Ventures and Tichenor Ventures. The firm said it has now raised over $130M for the company.
posted on Monday, July 22, 2013 (Link to more information)
Related companies:
NGM Biopharmaceuticals
Related stories:
> NGM Biopharmaceuticals Get $51M
> Ardelyx Raises $30M
> Intarcia Therapeutics Gets $210M For Diabetes Treatments
> Scale Promotes Lynch
> Barosense Raises $27.4M
silicontap.com Home